Issue of Options & Transfer of Shares
13 March, 2012
Research Update
27 February, 2012
Half-Yearly Report
27 February, 2012
Notice of Results
30 January, 2012
Result of AGM
14 December, 2011
News feed
requires RSS news reader
| Sareum Holdings | |
| Last Trading | 0.77 |
| Trade Time | 15:43am |
| Change | -0.08 |
| Open | 0.80 |
| Day's Range | 0.70 - 0.862 |
| Volume | 3924017 |
Sareum's small molecule drug discovery expertise is building value by developing drug candidates, focused on cancer and auto-immune disease, for licencing to pharmaceutical and biotechnology companies
Learn more about Sareum’s pipeline of targeted small molecule drug candidates
Dr Tim Mitchell, CEO and co-founder of Sareum, discusses the Company's business model, its "SKIL®" technology platform and the progress in its drug research pipeline in this video presentation.
Sareum Holdings Plc's house broker, Hybridan LLP, will from time to time publish research notes on the Company. You can download the research notes from this page. (Latest update: Feb 2012).
2011 Annual Report & Accounts is available for download here: Annual Report 2011
Website last updated on: 5-March-2012
Requires MS Word
Requires Adobe Acrobat Reader